Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D; CitAD Research Group. Peters ME, et al. Among authors: shade dm. J Geriatr Psychiatry Neurol. 2016 Mar;29(2):59-64. doi: 10.1177/0891988715601735. Epub 2015 Aug 23. J Geriatr Psychiatry Neurol. 2016. PMID: 26303700 Free PMC article. Clinical Trial.
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Porsteinsson AP, et al. Among authors: shade dm. JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93. JAMA. 2014. PMID: 24549548 Free PMC article. Clinical Trial.
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Drye LT, et al. Among authors: shade dm. PLoS One. 2014 Jun 10;9(6):e98426. doi: 10.1371/journal.pone.0098426. eCollection 2014. PLoS One. 2014. PMID: 24914549 Free PMC article. Clinical Trial.
Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG; CitAD Research Group. Weintraub D, et al. Among authors: shade dm. Am J Geriatr Psychiatry. 2015 Nov;23(11):1127-33. doi: 10.1016/j.jagp.2015.05.006. Epub 2015 May 19. Am J Geriatr Psychiatry. 2015. PMID: 26238225 Free PMC article. Clinical Trial.
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG; CitAD Research Group. Rosenberg PB, et al. Among authors: shade dm. Int Psychogeriatr. 2015 Dec;27(12):2059-67. doi: 10.1017/S1041610215001106. Epub 2015 Aug 25. Int Psychogeriatr. 2015. PMID: 26305876 Free PMC article. Clinical Trial.
Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease.
Hacker ML, Tonascia J, Turchan M, Currie A, Heusinkveld L, Konrad PE, Davis TL, Neimat JS, Phibbs FT, Hedera P, Wang L, Shi Y, Shade DM, Sternberg AL, Drye LT, Charles D. Hacker ML, et al. Among authors: shade dm. Parkinsonism Relat Disord. 2015 Oct;21(10):1177-83. doi: 10.1016/j.parkreldis.2015.08.008. Epub 2015 Aug 11. Parkinsonism Relat Disord. 2015. PMID: 26306000 Clinical Trial.
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.
Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG. Akil A, et al. Among authors: shade dm. J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):99-109. doi: 10.1007/s10928-015-9457-6. Epub 2015 Nov 26. J Pharmacokinet Pharmacodyn. 2016. PMID: 26611790 Free PMC article.
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A; CitAD Research Group. Newell J, et al. Among authors: shade dm. J Psychiatr Res. 2016 Mar;74:17-21. doi: 10.1016/j.jpsychires.2015.12.005. Epub 2015 Dec 12. J Psychiatr Res. 2016. PMID: 26736036 Free PMC article. Clinical Trial.
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Schneider LS, et al. Am J Psychiatry. 2016 May 1;173(5):465-72. doi: 10.1176/appi.ajp.2015.15050648. Epub 2016 Jan 15. Am J Psychiatry. 2016. PMID: 26771737 Free PMC article. Clinical Trial.
63 results